New medicines for Canavan Disease
Development of NAT8L inhibitors for the Treatment of Canavan Disease
This project aims to create new medicines that could help children with Canavan disease by lowering harmful levels of a substance in their brains.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11123221 on NIH RePORTER |
What this research studies
Canavan disease is a serious genetic condition that causes high levels of a substance called N-acetylaspartate (NAA) to build up in the brain, leading to severe problems with brain development and function. Currently, there are no treatments that can stop or reverse the progression of this disease. Our team is working to find and improve special medicines called NAT8L inhibitors, which are designed to reduce the amount of NAA in the brain. We hope these new medicines will help prevent the brain damage seen in Canavan disease and improve the lives of affected children.
Who could benefit from this research
Good fit: This foundational research is for children with Canavan disease, particularly those aged 0-11 years old, who currently lack effective treatment options.
Not a fit: Patients with conditions other than Canavan disease would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the first disease-modifying treatment for Canavan disease, potentially slowing or stopping its progression and improving brain health.
How similar studies have performed: Previous genetic studies in mouse models of Canavan disease have shown significant therapeutic benefits by disrupting the NAT8L gene, suggesting this approach is promising.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Tsukamoto, Takashi — Johns Hopkins University
- Study coordinator: Tsukamoto, Takashi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.